Search filters

List of works by Antje Hoering

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients

scientific article published in December 2017

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

scientific article

Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States

scientific article published on 30 June 2016

Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.

scientific article

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.

scientific article published on 3 November 2016

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

scientific article published on 3 October 2016

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

scientific article published in December 2007

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

scientific article published on 22 December 2016

Clinical trial designs for multiple myeloma.

scientific article published on April 2007

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).

scientific article published on 21 October 2013

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

scientific article published on 10 June 2009

Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.

scientific article

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials.

scientific article published on 6 July 2018

Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents

scientific article published on 25 March 2013

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma

scientific article published on 11 April 2017

Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays

scientific article

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

scientific article

First thalidomide clinical trial in multiple myeloma: a decade

scientific article published on 23 May 2008

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

scientific article published on 28 May 2015

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival

scientific article published on 23 April 2009

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping

scientific article published on 19 September 2008

Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival

scientific article

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy ⬇️

scientific article published on March 14, 2012

Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels

scientific article

International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols ⬇️

scientific article published on October 13, 2010

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

scientific article published on 25 August 2006

Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.

scientific article

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma

scientific article

Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma: Supplementary Data

scientific article published on 10 January 2019

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.

scientific article

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

scientific article published on 10 January 2013

Randomized phase III clinical trial designs for targeted agents

scientific article published on July 2008

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms

scientific article

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

scientific article published on 19 April 2013

Risk of multiple myeloma in a case-spouse study

scientific article

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents ⬇️

scientific article published on December 6, 2010

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance ⬇️

scientific article published on June 6, 2012

Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease

scientific article

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

scientific article

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1

scientific article published on August 2012

Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial

scientific article published in August 2006

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

scientific article published on 18 May 2017

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

scientific article published on 26 April 2016

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

scientific article

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma

scientific article published in June 2018

Paulina is supported by:

About Paulina

Help